TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer

Summary

Status - CLOSED TO PATIENT ENROLLMENT (CNPE) Patients who have pancreatic cancer that has come back or has not gone away after treatment, including the standard treatment for this disease or patients who are not eligible for or have elected not to receive standard of care chemotherapy, and patients who will have surgery after treatment for pancreatic cancer are eligible for this study. This is a research study using special immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy. The proteins that are targeted in this study are called tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They do not show, or they show up in low quantities, on normal human cells. In this study, five common TAAs will be targeted. They are called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX2. On a different study, patients have been treated and so far this treatment has shown to be safe. Investigators now want to try this treatment in patients with pancreatic cancer. These TAA-specific cytotoxic T lymphocytes (TAA-CTLs) are an investigational product not approved by the Food and Drug Administration. \*Arm A and Arm B are closed to new patient enrollment.\*

Timeline

Start

2018-01-18

Primary completion

2020-06-15

Completion

2025-07-31

Publications

• Musher BL, Vasileiou S, Smaglo BG, Robertson CS, Wu M, Wang T, Watanabe A, Kuvalekar M, Velazquez Y, Ketkar S, Doheyan TA, Papayanni PG, Shah A, Lapteva N, Grilley BJ, Van Buren G, Lulla PD, Heslop HE, Rooney CM, Brenner MK, Leen AM. Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Nat Med. 2026 Jan;32(1):258-269. doi: 10.1038/s41591-025-04043-5. Epub 2026 Jan 2.

Drugs

Indications